Most diabetes decisions happen outside the clinic, a reality now shaping a new category of digital health solutions.
DreaMed Diabetes reported new clinical investigation results from Slovenia showing that its MODI Dose Guidance Solution (DGS) demonstrated glycemic safety and improved glucose control. The findings were presented at ATTD 2026, one of the leading global conferences in diabetes technology. MODI DGS is currently an investigational device and is not yet available for sale.
The results point to a broader structural challenge in diabetes care. Management of a chronic condition like diabetes is inherently continuous, requiring frequent adjustments in insulin dosing and therapy based on daily changes in physiology and behavior. Yet healthcare models today remain episodic, with patients typically seeing clinicians only once every six months to a year.
As a result, most treatment decisions are made between visits. In the United States, only a minority of people with type 2 diabetes achieve recommended glycemic targets, despite well-established clinical guidelines.
This gap is further compounded by limited access to care. Approximately 70% of U.S. counties lack a diabetes specialist, while millions of patients who could benefit from continuous monitoring and data-driven tools remain underserved.
How Digital Solutions Are Addressing the Continuity-of-Care Gap
Continuous care for people with diabetes under insulin delivery is only available today for a small fraction of the population that uses insulin pumps and continuous glucose monitoring (CGM) devices. With the increasing adoption of CGM among the majority of insulin injection users, a growing category of digital solutions is emerging to address the continuity-of-care gap. Decision-support systems aim to translate clinical guidelines into day-to-day treatment recommendations. These tools extend clinical guidance into daily decision-making while maintaining physician oversight.
DreaMed operates within this category, supporting insulin management through clinically validated algorithms based on patient data. Its approach reflects a broader shift toward regulated software solutions designed to support people with diabetes between clinic visits, supported by a growing body of clinical evidence.
At the same time, the care environment is evolving. In the U.S., reimbursement structures are gradually adapting to support digital and remote clinical care, while adoption of connected health devices continues to expand. Only a fraction of the estimated CGM-eligible insulin-using population currently uses these technologies, suggesting room for continued adoption.
Beyond clinical care, these developments align with a wider shift toward data-driven health management. The rapid adoption of wearables and digital health tools is increasing both the availability of real-time patient data and the demand for actionable, clinically validated insights. Decision-support systems are a practical fit within this broader trend, supported by both structural healthcare needs and accelerating technology adoption.
What Comes Next for Software-Enabled Diabetes Care
This shift is not limited to diabetes. Across healthcare, the combination of continuous data streams, constrained clinical capacity, and evolving reimbursement models is driving a broader transition toward software-enabled care. Platforms that can translate growing volumes of patient data into structured, clinically actionable decisions are becoming increasingly relevant, not only within endocrinology but across other chronic conditions.
As clinical validation, regulatory guidance, reimbursement pathways, and data availability continue to align, the focus is shifting from proving the value of these tools to deploying them across broader patient populations. The pace of adoption and the approaches that prove most effective will shape how chronic conditions are managed in an increasingly data-driven healthcare environment.
